EFPIA calls for US-like voucher system to boost European antibiotic research

The pharmaceutical association says the priority review voucher in the US could be the way forward in Europe to nudge companies to research and develop new antibiotics.

Photo: Monika Skolimowska/AP/Ritzau Scanpix

European antimicrobial research and development needs a boost, and the implementation of a system like the priory review voucher in the US could be what gets the ball rolling, reports media Endpoints News citing research funded by the European Federation of Pharmaceutical Industries and Associations, EFPIA.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs